Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular Mycobacterium tuberculosis

被引:1
作者
Njikan, Samuel [1 ,2 ]
Ahmed, Sara [1 ,2 ]
Manning, Alyssa [1 ]
Awasthi, Divya [1 ]
Ovechkina, Yulia [1 ,2 ]
Chowdhury, Sultan [1 ,2 ]
Butts, Arielle [1 ,2 ]
Parish, Tanya [1 ,2 ]
机构
[1] Infect Dis Res Inst, Seattle, WA 98102 USA
[2] Seattle Childrens Res Inst, Ctr Global Infect Dis Res Seattle, Seattle, WA 98101 USA
来源
MICROBIOLOGY SPECTRUM | 2022年 / 10卷 / 03期
基金
美国国家卫生研究院;
关键词
high-content analysis; Mycobacterium tuberculosis; phenotypic screening; antibacterial drug discovery; DRUG DISCOVERY; DERIVATIVES; SURVIVAL; GENES; UREA;
D O I
10.1128/spectrum.01161-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mycobacterium tuberculosis is responsible for the highest number of deaths from a bacterial pathogen, with >1.5 million in 2020. M. tuberculosis is a sophisticated pathogen that can replicate inside immune cells. There is an urgent need for new drugs to combat M. tuberculosis and to shorten therapy from 6 to 24 months. We previously identified a phenylthiourea series with activity against intracellular Mycobacterium tuberculosis using a high-throughput, high-content assay. We conducted a catalog structure-activity relationship study with a collection of 35 analogs. We identified several thiourea derivatives with excellent potency against intracellular bacteria and good selectivity over eukaryotic cells. Compounds had much lower activity against extracellular bacteria, which was not increased by using cholesterol as the sole carbon source. Compounds were equally active against strains with mutations in QcrB or MmpL3, thereby excluding common, promiscuous targets as the mode of action. The phenylthiourea series represents a good starting point for further exploration to develop novel antitubercular agents. IMPORTANCE Mycobacterium tuberculosis is responsible for the highest number of deaths from a bacterial pathogen, with >1.5 million in 2020. M. tuberculosis is a sophisticated pathogen that can replicate inside immune cells. There is an urgent need for new drugs to combat M. tuberculosis and to shorten therapy from 6 to 24 months. We have identified a series of molecules that inhibit the growth of M. tuberculosis inside macrophages; we tested a number of derivatives to link structural features to biological activity. The compounds are likely to have novel mechanism of action and so could be developed as new agents for drug-resistant tuberculosis.
引用
收藏
页数:11
相关论文
共 31 条
  • [11] Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
    Ghosh, Arun K.
    Brindisi, Margherita
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (06) : 2751 - 2788
  • [12] Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?
    Goldman, Robert C.
    [J]. TUBERCULOSIS, 2013, 93 (06) : 569 - 588
  • [13] New agents for the treatment of drug-resistant Mycobacterium tuberculosis
    Hoagland, Daniel T.
    Liu, Jiuyu
    Lee, Robin B.
    Lee, Richard E.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2016, 102 : 55 - 72
  • [14] Mycobacterium tuberculosis: Bacterial Fitness within the Host Macrophage
    Huang, Lu
    Nazarova, Evgeniya, V
    Russell, David G.
    [J]. MICROBIOLOGY SPECTRUM, 2019, 7 (02):
  • [15] A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis
    Manning, Alyssa J.
    Ovechkina, Yulia
    McGillivray, Amanda
    Flint, Lindsay
    Roberts, David M.
    Parish, Tanya
    [J]. METHODS, 2017, 127 : 3 - 11
  • [16] Multiple Mutations in Mycobacterium tuberculosis MmpL3 Increase Resistance to MmpL3 Inhibitors
    McNeil, Matthew B.
    O'malley, Theresa
    Dennison, Devon
    Shelton, Catherine D.
    Sunde, Bjorn
    Parish, Tanya
    [J]. MSPHERE, 2020, 5 (05):
  • [17] Tuberculosis drug discovery and emerging targets
    Mdluli, Khisimuzi
    Kaneko, Takushi
    Upton, Anna
    [J]. ANTIMICROBIAL THERAPEUTICS REVIEWS: INFECTIOUS DISEASES OF CURRENT AND EMERGING CONCERN, 2014, 1323 : 56 - 75
  • [18] The Tuberculous Granuloma: An Unsuccessful Host Defence Mechanism Providing a Safety Shelter for the Bacteria?
    Miranda, Mayra Silva
    Breiman, Adrien
    Allain, Sophie
    Deknuydt, Florence
    Altare, Frederic
    [J]. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [19] A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis
    Ollinger, Juliane
    Bailey, Mai Ann
    Moraski, Garrett C.
    Casey, Allen
    Florio, Stephanie
    Alling, Torey
    Miller, Marvin J.
    Parish, Tanya
    [J]. PLOS ONE, 2013, 8 (04):
  • [20] In vitro drug discovery models for Mycobacterium tuberculosis relevant for host infection
    Parish, Tanya
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2020, 15 (03) : 349 - 358